Csóka I - Search Results

1

Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.

Karimi K, Pallagi E, Szabó-Révész P, Csóka I, Ambrus R. Karimi K, et al. Among authors: csoka i. Drug Des Devel Ther. 2016 Oct 12;10:3331-3343. doi: 10.2147/DDDT.S116443. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27784991 Free PMC article.

2

Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.

Pallagi E, Ambrus R, Szabó-Révész P, Csóka I. Pallagi E, et al. Among authors: csoka i. Int J Pharm. 2015 Aug 1;491(1-2):384-92. doi: 10.1016/j.ijpharm.2015.06.018. Epub 2015 Jun 29. Int J Pharm. 2015. PMID: 26134895

3

New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach.

Pallagi E, Karimi K, Ambrus R, Szabó-Révész P, Csóka I. Pallagi E, et al. Among authors: csoka i. Int J Pharm. 2016 Sep 10;511(1):151-160. doi: 10.1016/j.ijpharm.2016.07.003. Epub 2016 Jul 4. Int J Pharm. 2016. PMID: 27386791

4

Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method.

Kovács A, Berkó S, Csányi E, Csóka I. Kovács A, et al. Among authors: csoka i. Eur J Pharm Sci. 2017 Mar 1;99:246-257. doi: 10.1016/j.ejps.2016.12.020. Epub 2016 Dec 21. Eur J Pharm Sci. 2017. PMID: 28012940 Free article.

5

Preliminary study of nanonized lamotrigine containing products for nasal powder formulation.

Gieszinger P, Csóka I, Pallagi E, Katona G, Jójárt-Laczkovich O, Szabó-Révész P, Ambrus R. Gieszinger P, et al. Among authors: csoka i. Drug Des Devel Ther. 2017 Aug 23;11:2453-2466. doi: 10.2147/DDDT.S138559. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28860716 Free PMC article.

6

Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.

Karimi K, Katona G, Csóka I, Ambrus R. Karimi K, et al. Among authors: csoka i. J Pharm Biomed Anal. 2018 Jan 30;148:73-79. doi: 10.1016/j.jpba.2017.09.019. Epub 2017 Sep 22. J Pharm Biomed Anal. 2018. PMID: 28965047

7

Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes.

Csóka I, Pallagi E, Paál TL. Csóka I, et al. Drug Discov Today. 2018 Jul;23(7):1340-1343. doi: 10.1016/j.drudis.2018.03.012. Epub 2018 Mar 27. Drug Discov Today. 2018. PMID: 29601866 Free article. Review.

8

Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.

Alshweiat A, Katona G, Csóka I, Ambrus R. Alshweiat A, et al. Among authors: csoka i. Eur J Pharm Sci. 2018 Sep 15;122:94-104. doi: 10.1016/j.ejps.2018.06.010. Epub 2018 Jun 14. Eur J Pharm Sci. 2018. PMID: 29908301

9

Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development.

Pallagi E, Ismail R, Paál TL, Csóka I. Pallagi E, et al. Among authors: csoka i. Eur J Pharm Sci. 2018 Sep 15;122:160-169. doi: 10.1016/j.ejps.2018.07.003. Epub 2018 Jul 3. Eur J Pharm Sci. 2018. PMID: 30008428 Free article.

10

Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.

Bartos C, Pallagi E, Szabó-Révész P, Ambrus R, Katona G, Kiss T, Rahimi M, Csóka I. Bartos C, et al. Among authors: csoka i. Eur J Pharm Sci. 2018 Oct 15;123:475-483. doi: 10.1016/j.ejps.2018.07.061. Epub 2018 Aug 1. Eur J Pharm Sci. 2018. PMID: 30076956

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters